基蛋生物再度逼近漲停 新冠抗原自測產品獲泰國、馬來官方認證
格隆匯11月26日丨繼昨日漲停後,基蛋生物(603387.SH)今早再度逼近漲停,最高報21.75元,市值79億元。近日,由基蛋生物自主研發、自主生產的新型冠狀病毒(SARS-CoV-2)抗原檢測試劑盒(膠體金法)產品分別獲得泰國食品藥品管理局TFDA和馬來西亞醫療器械管理局MDA的自測認證,獲准在兩國上市以用於民眾自我檢測新冠病毒感染情況。除了此次獲得泰國TFDA、馬來西亞MDA認證,基蛋生物新冠抗原自測試劑更是早在7月份就獲得歐盟CE認證,獲准在歐盟全境合法銷售。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.